Testing a new drug called GLIX1 in adults whose high grade glioma has come back or grown
Official title: A Phase 1 Safety and Dose Finding Study of GLIX1 in Adults With Recurrent or Progressive High-grade Glioma
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on .
The short version
This study is testing how safe the drug GLIX1 is, and what dose to use, in adults whose high grade glioma: A tumor that starts in the glial cells, the support cells of the brain and spinal cord. Gliomas are graded 1 to 4 by how fast they tend to grow. See the glossary has come back or kept growing.
Read our full plain-language summary
What the trial team says
This is an open-label, multicenter dose-escalation study to be followed by a dose expansion to define the optimal dose of GLIX1 as monotherapy by reviewing safety and tolerability, disease characteristics and pharmacokinetic profiles and preliminary clinical activity in participants with a high grade diffuse glioma that progressed during or recurred after prior standard of care therapies or investigational therapies as clinically indicated. Patients will be treated daily with GLIX1 capsules until disease progression or unacceptable safety.
Key facts
- Registry number
- NCT07464925
- Stage of testing
- Phase 1
- Conditions studied
- Glioblastoma Multiforme of Brain, Glioma, Glioblastoma
Where it is running
This trial lists 3 sites.
-
Florida
- Moffitt Cancer Center (Tampa)
-
Illinois
- Northwestern Medicine (Chicago)
-
New York
- NYU Langone Health (New York)
How to use this
Talk to your care team first. They know your history and can tell you whether this trial is worth your time.
Joining a trial is always your choice. A trial is a test, not a proven treatment. Being in one is not a promise that it will help you.
This page is built from the trial's listing on ClinicalTrials.gov, a service of the U.S. National Library of Medicine. That listing is the authority, and it may have changed since we last read it. We do not run this trial and we cannot enroll you in it.